About CytomX Therapeutics, Inc.
https://www.cytomx.comCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer.
CEO
Sean A. McCarthy DPHIL
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 53
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VR ADVISER, LLC
Shares:15.56M
Value:$66.91M
FMR LLC
Shares:15.4M
Value:$66.2M
TANG CAPITAL MANAGEMENT LLC
Shares:11.07M
Value:$47.58M
Summary
Showing Top 3 of 127
About CytomX Therapeutics, Inc.
https://www.cytomx.comCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.96M ▼ | $21.73M ▲ | $-14.23M ▼ | -238.62% ▼ | $-0.09 ▼ | $-14.04M ▼ |
| Q2-2025 | $18.66M ▼ | $19.94M ▼ | $-154K ▼ | -0.83% ▼ | $-0 ▼ | $-939K ▼ |
| Q1-2025 | $50.92M ▲ | $28.3M ▲ | $23.52M ▲ | 46.2% ▼ | $0.27 ▲ | $23.01M ▲ |
| Q4-2024 | $38.09M ▲ | $20.41M ▼ | $18.88M ▲ | 49.55% ▲ | $0.24 ▲ | $18.09M ▲ |
| Q3-2024 | $33.43M | $29.32M | $5.74M | 17.16% | $0.07 | $4.54M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $143.63M ▼ | $158.25M ▼ | $50.87M ▼ | $107.39M ▼ |
| Q2-2025 | $158.09M ▲ | $175.06M ▲ | $55.15M ▼ | $119.91M ▲ |
| Q1-2025 | $79.89M ▼ | $98.5M ▼ | $73.45M ▼ | $25.05M ▲ |
| Q4-2024 | $100.62M ▼ | $120.53M ▼ | $120.99M ▼ | $-456K ▲ |
| Q3-2024 | $117.59M | $138.98M | $162.43M | $-23.45M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-14.23M ▼ | $-15.55M ▲ | $439K ▲ | $253K ▼ | $-14.86M ▼ | $-15.42M ▲ |
| Q2-2025 | $-154K ▼ | $-15.75M ▲ | $-76.36M ▼ | $93.55M ▲ | $1.44M ▼ | $-15.78M ▲ |
| Q1-2025 | $23.52M ▲ | $-21.04M ▼ | $30.6M ▲ | $0 ▼ | $9.55M ▲ | $-21.16M ▼ |
| Q4-2024 | $18.88M ▲ | $-19.91M ▲ | $15.13M ▼ | $2.25M ▲ | $-2.52M ▲ | $-19.99M ▲ |
| Q3-2024 | $5.74M | $-20.73M | $18.17M | $0 | $-2.56M | $-20.75M |
CEO
Sean A. McCarthy DPHIL
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 53
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VR ADVISER, LLC
Shares:15.56M
Value:$66.91M
FMR LLC
Shares:15.4M
Value:$66.2M
TANG CAPITAL MANAGEMENT LLC
Shares:11.07M
Value:$47.58M
Summary
Showing Top 3 of 127